An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris

Neal D Bhatia

doi:10.25251/skin.1.supp.137

Neal D Bhatia

Keywords

ingenol mebutate, verruca vulgaris, efficacy, safety

Abstract

Abstract Not Available

Poster PDF

Published

Oct 27, 2017

DOI https://doi.org/10.25251/skin.1.supp.137

How to Cite

Bhatia, N. D. (2017). An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris. SKIN The Journal of Cutaneous Medicine, 1(3.1), s138. https://doi.org/10.25251/skin.1.supp.137

Issue

Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

Section

Miscellaneous

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal D Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart, Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, James Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, James Q Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, James Q Del Rosso, Neal D Bhatia, et al., Efficacy and Safety of FMX103 (1.5% Minocycline Foam) in the Treatment of Moderate to Severe Papulopustular Rosacea: Results from two Phase 3 Randomized, Multicenter, Double Blind, Vehicle Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Neal D Bhatia, Seemal R Desai, Craig Teller, Abby Jacobson, Maintenance and Improvement of Skin Clearance Response With Brodalumab Among Patients With Moderate-to-Severe Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)